Aaron Seth Kesselheim, M.D.
This page shows the publications co-authored by Aaron Kesselheim and Daniel Solomon.
Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. J Gen Intern Med. 2015 Nov; 30(11):1633-8.
Incentives for drug development--the curious case of colchicine. N Engl J Med. 2010 Jun 03; 362(22):2045-7.
Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act. Ann Intern Med. 2019 10 15; 171(8):578-579.
Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea. Arthritis Rheumatol. 2016 05; 68(5):1076-9.
The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012; 7(2):e31894.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.